Alexander J. Bridges

Author

Also Known As

A J Bridges, A. Bridges, A. J. BRIDGES, A. J. Bridges, ALEXANDER J. BRIDGES, Alexander Bridges, Alexander J Bridges, Alexander J. Bridges

100

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

University of Auckland Pfizer (United States)Cancer Society of New Zealand Eisai (Japan)Gaertner (United States)

About

Alexander J. Bridges is an author at University of Auckland specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	20	5.9K
2	Natural Sciences	14	15	1.3K
3	Engineering	12	14	412
4	Biochemistry	12	12	1.3K
5	Health Sciences	1	1	25

Alexander J. Bridges

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
A synthetic inhibitor of the mitogen-activated protein kinase cascade. David T. Dudley, Long Pang, Stuart J. Decker, Proceedings of the National Academy of Sciences Signal TransductionPd 098059Cell RegulationSignaling PathwayMedicine	1995	2.7K
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Judith S. Sebolt–Leopold, David T. Dudley, Román Herrera, Nature Medicine Colon TumorsMedicineReceptor Tyrosine KinasePathologyColorectal Cancer	1999	965
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase David W. Fry, Alan J. Kraker, Amy McMichael, Science Specific InhibitorCancer ResearchSignal TransductionSignaling PathwayMedicine	1994	801
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor David W. Fry, Alexander J. Bridges, William A. Denny, Proceedings of the National Academy of Sciences Drug TargetCell GrowthChemical BiologyMedicinal ChemistrySignaling Pathway	1998	417
Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor Alexander J. Bridges, Hairong Zhou, Donna R. Cody, Journal of Medicinal Chemistry	1996	321
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 Stephen D. Barrett, Alexander J. Bridges, David T. Dudley, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetBiochemistryNatural SciencesMedicine	2008	280
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. Gordon W. Rewcastle, William A. Denny, Alexander J. Bridges, Journal of Medicinal Chemistry	1995	259
Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[<i>d</i>]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor Jeff B. Smaill, Brian D. Palmer, Gordon W. Rewcastle, Journal of Medicinal Chemistry	1999	178
Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor Gordon W. Rewcastle, Brian D. Palmer, Alexander J. Bridges, Journal of Medicinal Chemistry	1996	149
Tyrosine kinase inhibitors. 7. 7-amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor Andrew M. Thompson, Alexander J. Bridges, David W. Fry, Journal of Medicinal Chemistry	1995	141

Page 1